203 related articles for article (PubMed ID: 21144054)
1. Differential expression of anterior gradient gene AGR2 in prostate cancer.
Maresh EL; Mah V; Alavi M; Horvath S; Bagryanova L; Liebeskind ES; Knutzen LA; Zhou Y; Chia D; Liu AY; Goodglick L
BMC Cancer; 2010 Dec; 10():680. PubMed ID: 21144054
[TBL] [Abstract][Full Text] [Related]
2. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer.
Zhang JS; Gong A; Cheville JC; Smith DI; Young CY
Genes Chromosomes Cancer; 2005 Jul; 43(3):249-59. PubMed ID: 15834940
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer cell phenotypes based on AGR2 and CD10 expression.
Ho ME; Quek SI; True LD; Morrissey C; Corey E; Vessella RL; Dumpit R; Nelson PS; Maresh EL; Mah V; Alavi M; Kim SR; Bagryanova L; Horvath S; Chia D; Goodglick L; Liu AY
Mod Pathol; 2013 Jun; 26(6):849-59. PubMed ID: 23348903
[TBL] [Abstract][Full Text] [Related]
4. Cancer-secreted AGR2 induces programmed cell death in normal cells.
Vitello EA; Quek SI; Kincaid H; Fuchs T; Crichton DJ; Troisch P; Liu AY
Oncotarget; 2016 Aug; 7(31):49425-49434. PubMed ID: 27283903
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients.
Zhang Y; Forootan SS; Liu D; Barraclough R; Foster CS; Rudland PS; Ke Y
Prostate Cancer Prostatic Dis; 2007; 10(3):293-300. PubMed ID: 17457305
[TBL] [Abstract][Full Text] [Related]
6. The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection.
Bu H; Bormann S; Schäfer G; Horninger W; Massoner P; Neeb A; Lakshmanan VK; Maddalo D; Nestl A; Sültmann H; Cato AC; Klocker H
Prostate; 2011 May; 71(6):575-87. PubMed ID: 20945500
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men.
Timofeeva OA; Zhang X; Ressom HW; Varghese RS; Kallakury BV; Wang K; Ji Y; Cheema A; Jung M; Brown ML; Rhim JS; Dritschilo A
Int J Oncol; 2009 Oct; 35(4):751-60. PubMed ID: 19724911
[TBL] [Abstract][Full Text] [Related]
8. ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer.
Zhang Y; Ali TZ; Zhou H; D'Souza DR; Lu Y; Jaffe J; Liu Z; Passaniti A; Hamburger AW
Cancer Res; 2010 Jan; 70(1):240-8. PubMed ID: 20048076
[TBL] [Abstract][Full Text] [Related]
9. Can telomere alterations predict biochemical recurrence in prostate adenocarcinoma? A preliminary study.
Baydar DE; Ozen H; Geyik PO; Gurel B
Pathol Res Pract; 2010 Oct; 206(10):700-4. PubMed ID: 20674190
[TBL] [Abstract][Full Text] [Related]
10. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma.
Fixemer T; Remberger K; Bonkhoff H
Prostate; 2003 Feb; 54(2):79-87. PubMed ID: 12497580
[TBL] [Abstract][Full Text] [Related]
12. High expression of AGR2 in lung cancer is predictive of poor survival.
Alavi M; Mah V; Maresh EL; Bagryanova L; Horvath S; Chia D; Goodglick L; Liu AY
BMC Cancer; 2015 Oct; 15():655. PubMed ID: 26445321
[TBL] [Abstract][Full Text] [Related]
13. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H
J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.
Tassidis H; Brokken LJ; Jirström K; Ehrnström R; Pontén F; Ulmert D; Bjartell A; Härkönen P; Wingren AG
Int J Cancer; 2010 May; 126(10):2296-307. PubMed ID: 19795453
[TBL] [Abstract][Full Text] [Related]
15. Expression of AGR2 in non small cell lung cancer.
Fritzsche FR; Dahl E; Dankof A; Burkhardt M; Pahl S; Petersen I; Dietel M; Kristiansen G
Histol Histopathol; 2007 Jul; 22(7):703-8. PubMed ID: 17455144
[TBL] [Abstract][Full Text] [Related]
16. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.
Stumm L; Burkhardt L; Steurer S; Simon R; Adam M; Becker A; Sauter G; Minner S; Schlomm T; Sirma H; Michl U
J Clin Pathol; 2013 Jul; 66(7):563-8. PubMed ID: 23559350
[TBL] [Abstract][Full Text] [Related]
17. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
18. Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential.
Ruela-de-Sousa RR; Hoekstra E; Hoogland AM; Souza Queiroz KC; Peppelenbosch MP; Stubbs AP; Pelizzaro-Rocha K; van Leenders GJLH; Jenster G; Aoyama H; Ferreira CV; Fuhler GM
Eur Urol; 2016 Apr; 69(4):710-719. PubMed ID: 26159288
[TBL] [Abstract][Full Text] [Related]
19. AGR2 expression in ovarian tumours: a potential biomarker for endometrioid and mucinous differentiation.
Armes JE; Davies CM; Wallace S; Taheri T; Perrin LC; Autelitano DJ
Pathology; 2013 Jan; 45(1):49-54. PubMed ID: 23222243
[TBL] [Abstract][Full Text] [Related]
20. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype.
Kani K; Malihi PD; Jiang Y; Wang H; Wang Y; Ruderman DL; Agus DB; Mallick P; Gross ME
Prostate; 2013 Feb; 73(3):306-15. PubMed ID: 22911164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
